MMP9 Rekombinanter Antikörper

MMP9 Rekombinant Antikörper für FC (Intra)

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

Maus

Anwendung

FC (Intra)

Konjugation

FITC Plus Fluorescent Dye

CloneNo.

230069F1

Kat-Nr. : FITC-98396

Synonyme

230069F1, AW743869, B/MMP9, Clg4b, matrix metallopeptidase 9



Geprüfte Anwendungen

Erfolgreiche Detektion in FC (Intra)mit LPS und Brefeldin A behandelte RAW 264.7-Zellen

Empfohlene Verdünnung

AnwendungVerdünnung
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, check data in validation data gallery

Produktinformation

FITC-98396 bindet in FC (Intra) MMP9 und zeigt Reaktivität mit Maus

Getestete Reaktivität Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Rekombinant
Typ Antikörper
Immunogen MMP9 fusion protein Eg0452
Vollständiger Name matrix metallopeptidase 9
Berechnetes Molekulargewicht81kd
GenBank-ZugangsnummerNM_013599
Gene symbol Mmp9
Gene ID (NCBI) 17395
Konjugation FITC Plus Fluorescent Dye
Excitation/Emission maxima wavelengths495 nm / 524 nm
Form Liquid
Reinigungsmethode Protein-A-Reinigung
Lagerungspuffer PBS with 0.09% sodium azide
LagerungsbedingungenStore at 2-8°C. Avoid exposure to light. Stable for one year after shipment.

Hintergrundinformationen

MMP9 (matrix metallopeptidase 9), also named as Gelatinase B, is a member of matrix metalloproteinase (MMP) family. The MMP family of enzymes is comprised of critically important extracellular matrix remodeling proteases whose activity has been implicated in normal embryogenesis, tissue remodelling and many diseases such as arthritis, cancer, periodontitis, glomerulonephritis, encephalomyelitis, atherosclerosis and tissue ulceration. MMP9 is produced by a variety of normal and transformed cells including neutrophils, monocytes, macrophages, astrocytes, fbroblasts, osteoclasts and so on. Transgenic mouse models report that MMP9 contributes to skin carcinogenesis, suppresses development of experimental abdominal aortic aneurysms, and triggers the angiogenic switch during carcinogenesis.

Protokolle

PRODUKTSPEZIFISCHE PROTOKOLLE
FC protocol for FITC Plus MMP9 antibody FITC-98396Download protocol
STANDARD-PROTOKOLLE
Klicken Sie hier, um unsere Standardprotokolle anzuzeigen